BM
BPMC

Bridger Management’s Blueprint Medicines BPMC Stock Holding History

Bridger Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53,300
Closed -$3.51M – 27
2022
Q3 		$3.51M Buy
+53,300
New +$3.42M 1.06% 27

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bridger Management's BPMC Position: Q4 2022 in Review

Bridger Management sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 53,300 shares — an estimated $3.51M sold.

Bridger Management first reported a position in BPMC in Q3 2022 and held it in 1 quarter. The position peaked at $3.51M in Q3 2022. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Bridger Management reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Bridger Management sold 53,300 Blueprint Medicines shares in Q4 2022, an estimated $3.51M.
  • Bridger Management first reported a position in Blueprint Medicines in Q3 2022 and held it in 1 quarter.
  • Bridger Management's Blueprint Medicines position peaked at $3.51M in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Bridger Management's 13F filing for Q4 2022, filed 15 Feb 2023.